SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-11-091390
Filing Date
2011-04-07
Accepted
2011-04-07 17:20:20
Documents
7
Period of Report
2010-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K AMENDMENT NO. 1 d10ka.htm 10-K/A 1105530
2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM dex231.htm EX-23.1 1822
3 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM dex232.htm EX-23.2 1618
4 SECTION 302 CEO CERTIFICATION dex311.htm EX-31.1 10716
5 SECTION 302 CFO CERTIFICATION dex312.htm EX-31.2 10893
6 SECTION 906 CEO CERTIFICATION dex321.htm EX-32.1 3239
7 SECTION 906 CFO CERTIFICATION dex322.htm EX-32.2 3442
  Complete submission text file 0001193125-11-091390.txt   1138318
Mailing Address 3530 TORINGDON WAY SUITE 200 CHARLOTTE NC 28277
Business Address 3530 TORINGDON WAY SUITE 200 CHARLOTTE NC 28277 704-341-1516
Chelsea Therapeutics International, Ltd. (Filer) CIK: 0001333763 (see all company filings)

IRS No.: 203174202 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 000-51462 | Film No.: 11746927
SIC: 2836 Biological Products, (No Diagnostic Substances)